Hepatology

Article	Citations
Epidemiology of Hepatocellular Carcinoma	995
Diagnosis and Management of Autoimmune Hepatitis in Adults and Children: 2019 Practice Guidance and Guidelines From the American Association for the Study of Liver Diseases	470
The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review	436
Changes in the Global Burden of Chronic Liver Diseases From 2012 to 2017: The Growing Impact of NAFLD	435
AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease	423
A multisociety Delphi consensus statement on new fatty liver disease nomenclature	345
Diagnosis, Evaluation, and Management of Ascites, Spontaneous Bacterial Peritonitis and Hepatorenal Syndrome: 2021 Practice Guidance by the American Association for the Study of Liver Diseases	318
Clinical Best Practice Advice for Hepatology and Liver Transplant Providers During the COVID‐19 Pandemic: AASLD Expert Panel Consensus Statement	316
Longitudinal Association Between Markers of Liver Injury and Mortality in COVID‐19 in China	303
Vascular Liver Disorders, Portal Vein Thrombosis, and Procedural Bleeding in Patients With Liver Disease: 2020 Practice Guidance by the American Association for the Study of Liver Diseases	300
Malnutrition, Frailty, and Sarcopenia in Patients With Cirrhosis: 2021 Practice Guidance by the American Association for the Study of Liver Diseases	273
Acute Liver Injury in COVID‐19: Prevalence and Association with Clinical Outcomes in a Large U.S. Cohort	254
From NAFLD to MAFLD: Implications of a Premature Change in Terminology	249
Cenicriviroc Treatment for Adults With Nonalcoholic Steatohepatitis and Fibrosis: Final Analysis of the Phase 2b CENTAUR Study	223
Trial Design and Endpoints in Hepatocellular Carcinoma: AASLD Consensus Conference	219
Cilofexor, a Nonsteroidal FXR Agonist, in Patients With Noncirrhotic NASH: A Phase 2 Randomized Controlled Trial	215
Yttrium‐90 Radioembolization for the Treatment of Solitary, Unresectable HCC: The LEGACY Study	213
Abnormal Liver Function Tests in Patients With COVID‐19: Relevance and Potential Pathogenesis	211
Increased Liver Localization of Lipopolysaccharides in Human and Experimental NAFLD	201
Detection of Circulating Tumor Cells and Their Implications as a Biomarker for Diagnosis, Prognostication, and Therapeutic Monitoring in Hepatocellular Carcinoma	191
Multiple Parallel Hits Hypothesis in Nonalcoholic Fatty Liver Disease: Revisited After a Decade	191
AASLD Practice Guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma	185
Abnormal Liver Tests in COVID‐19: A Retrospective Observational Cohort Study of 1,827 Patients in a Major U.S. Hospital Network	183
Hepatic fibrosis 2022: Unmet needs and a blueprint for the future	179
Saroglitazar, a PPAR‐α/γ Agonist, for Treatment of NAFLD: A Randomized Controlled Double‐Blind Phase 2 Trial	174

Combination Therapies Including Cilofexor and Firsocostat for Bridging Fibrosis and Cirrhosis Attributable to NASH	157
Identification of Four Immune Subtypes Characterized by Distinct Composition and Functions of Tumor Microenvironment in Intrahepatic Cholangiocarcinoma	157
Predicting Survival After Hepatocellular Carcinoma Resection Using Deep Learning on Histological Slides	156
Lipotoxic Hepatocyte‐Derived Exosomal MicroRNA 192‐5p Activates Macrophages Through Rictor/Akt/Forkhead Box Transcription Factor O1 Signaling in Nonalcoholic Fatty Liver Disease	156
Circular RNA Sequencing Identifies CircASAP1 as a Key Regulator in Hepatocellular Carcinoma Metastasis	155
Coronavirus Disease 2019 Hangover: A Rising Tide of Alcohol Use Disorder and Alcohol‐Associated Liver Disease	151
Cancer‐Associated Fibroblast‐Mediated Cellular Crosstalk Supports Hepatocellular Carcinoma Progression	150
Use of Hepatocellular Carcinoma Surveillance in Patients With Cirrhosis: A Systematic Review and Meta‐Analysis	146
Lenvatinib Targets FGF Receptor 4 to Enhance Antitumor Immune Response of Anti–Programmed Cell Death‐1 in HCC	146
Combined Effect of PNPLA3, TM6SF2, and HSD17B13 Variants on Risk of Cirrhosis and Hepatocellular Carcinoma in the General Population	136
Hepatotoxicity From Immune Checkpoint Inhibitors: A Systematic Review and Management Recommendation	133
Liver Biochemistries in Hospitalized Patients With COVID‐19	130
Immune‐Responsive Gene 1/Itaconate Activates Nuclear Factor Erythroid 2–Related Factor 2 in Hepatocytes to Protect Against Liver Ischemia–Reperfusion Injury	124
Transmission of Rat Hepatitis E Virus Infection to Humans in Hong Kong: A Clinical and Epidemiological Analysis	119
A Randomized Clinical Trial of Fecal Microbiota Transplant for Alcohol Use Disorder	116
The liver cancer immune microenvironment: Therapeutic implications for hepatocellular carcinoma	116
Lysyl Oxidase (LOX) Family Members: Rationale and Their Potential as Therapeutic Targets for Liver Fibrosis	115
Population screening for liver fibrosis: Toward early diagnosis and intervention for chronic liver diseases	115
American Association for the Study of Liver Diseases Expert Panel Consensus Statement: Vaccines to Prevent Coronavirus Disease 2019 Infection in Patients With Liver Disease	115
Retracted: M2 Macrophage–Derived Exosomes Facilitate HCC Metastasis by Transferring αMβ2 Integrin to Tumor Cells	112
Preliminary evidence of safety and tolerability of atezolizumab plus bevacizumab in patients with hepatocellular carcinoma and Child‐Pugh A and B cirrhosis: A real‐world study	112
N6‐Methyladenosine Reader Protein YT521‐B Homology Domain‐Containing 2 Suppresses Liver Steatosis by Regulation of mRNA Stability of Lipogenic Genes	108
Telemedicine in Liver Disease and Beyond: Can the COVID‐19 Crisis Lead to Action?	107
Impact of Alcohol Use Disorder Treatment on Clinical Outcomes Among Patients With Cirrhosis	106
A Machine Learning Approach Enables Quantitative Measurement of Liver Histology and Disease Monitoring in NASH	105
Insights into modifiable risk factors of cholelithiasis: A Mendelian randomization study	105
Administrative Coding in Electronic Health Care Record‐Based Research of NAFLD: An Expert Panel Consensus Statement	105
A Circular RNA, Cholangiocarcinoma‐Associated Circular RNA 1, Contributes to Cholangiocarcinoma Progression, Induces Angiogenesis, and Disrupts Vascular Endothelial Barriers	102
High‐quality diet, physical activity, and college education are associated with low risk of NAFLD among the US population	102
Pregenomic HBV RNA and Hepatitis B Core‐Related Antigen Predict Outcomes in Hepatitis B e Antigen–Negative Chronic Hepatitis B Patients Suppressed on Nucleos(T)ide Analogue Therapy	101
Myeloid‐Cell–Specific IL‐6 Signaling Promotes MicroRNA‐223‐Enriched Exosome Production to Attenuate NAFLD‐Associated Fibrosis	99
Emerging immunotherapy for HCC: A guide for hepatologists	99
Iron Chaperone Poly rC Binding Protein 1 Protects Mouse Liver From Lipid Peroxidation and Steatosis	99
The Tumor Microenvironment in Cholangiocarcinoma Progression	98
Biomarkers for Hepatobiliary Cancers	98
Microbiota‐Driven Activation of Intrahepatic B Cells Aggravates NASH Through Innate and Adaptive Signaling	97
Treatment of Hepatocellular Carcinoma in the Precision Medicine Era: From Treatment Stage Migration to Therapeutic Hierarchy	97
Thyroid Hormone Signaling and the Liver	96
Immunomodulatory Effects of Lenvatinib Plus Anti–Programmed Cell Death Protein 1 in Mice and Rationale for Patient Enrichment in Hepatocellular Carcinoma	95
Application of Artificial Intelligence for the Diagnosis and Treatment of Liver Diseases	93
Surgical Treatments of Hepatobiliary Cancers	93
Cancer Risk in Patients With Biopsy‐Confirmed Nonalcoholic Fatty Liver Disease: A Population‐Based Cohort Study	91
SIRT1 Regulates N6‐Methyladenosine RNA Modification in Hepatocarcinogenesis by Inducing RANBP2‐Dependent FTO SUMOylation	91
Osteopontin Takes Center Stage in Chronic Liver Disease	90
Prenatal Exposure to Perfluoroalkyl Substances Associated With Increased Susceptibility to Liver Injury in Children	89
Perioperative Presentation of COVID‐19 Disease in a Liver Transplant Recipient	88
NAFLD: Reporting Histologic Findings in Clinical Practice	87
Hepatocellular Carcinoma Demonstrates Heterogeneous Growth Patterns in a Multicenter Cohort of Patients With Cirrhosis	86
Prediction of Survival Among Patients Receiving Transarterial Chemoembolization for Hepatocellular Carcinoma: A Response‐Based Approach	85
Compromised hepatic mitochondrial fatty acid oxidation and reduced markers of mitochondrial turnover in human NAFLD	84

HBV‐Induced Increased N6 Methyladenosine Modification of PTEN RNA Affects Innate Immunity and Contributes to HCC	84
Sirt6 Alleviated Liver Fibrosis by Deacetylating Conserved Lysine 54 on Smad2 in Hepatic Stellate Cells	84
Global burden of NAFLD and chronic liver disease among adolescents and young adults	83
Risk Prediction Models for Post‐Operative Mortality in Patients With Cirrhosis	82
Genetic Pathways in Nonalcoholic Fatty Liver Disease: Insights From Systems Biology	81
Single‐Cell Transcriptomic Analysis Reveals a Hepatic Stellate Cell–Activation Roadmap and Myofibroblast Origin During Liver Fibrosis in Mice	81
A Systematic Review of Animal Models of NAFLD Finds High‐Fat, High‐Fructose Diets Most Closely Resemble Human NAFLD	79
Transcriptomics Identify Thrombospondin‐2 as a Biomarker for NASH and Advanced Liver Fibrosis	78
CAFs shape myeloid‐derived suppressor cells to promote stemness of intrahepatic cholangiocarcinoma through 5‐lipoxygenase	78
Role of the Mammalian Target of Rapamycin Pathway in Liver Cancer: From Molecular Genetics to Targeted Therapies	77
Fatty Acid Synthase Inhibitor TVB‐2640 Reduces Hepatic de Novo Lipogenesis in Males With Metabolic Abnormalities	77
AASLD practice guidance on primary sclerosing cholangitis and cholangiocarcinoma	77
Hypoxia‐Inducible Exosomes Facilitate Liver‐Tropic Premetastatic Niche in Colorectal Cancer	77
PPARγ Coactivator‐1α Suppresses Metastasis of Hepatocellular Carcinoma by Inhibiting Warburg Effect by PPARγ–Dependent WNT/β‐Catenin/Pyruvate Dehydrogenase Kinase Isozyme 1 Axis	77
Multicenter Validation of Association Between Decline in MRI‐PDFF and Histologic Response in NASH	77
Are there outcome differences between NAFLD and metabolic‐associated fatty liver disease?	77
Lipid Remodeling in Hepatocyte Proliferation and Hepatocellular Carcinoma	76
IL‐1β‐Induced Elevation of Solute Carrier Family 7 Member 11 Promotes Hepatocellular Carcinoma Metastasis Through Up‐regulating Programmed Death Ligand 1 and Colony‐Stimulating Factor 1	75
Genetic Determinants of Outcome in Intrahepatic Cholangiocarcinoma	75
Intestinal Virome in Patients With Alcoholic Hepatitis	74
Hypoxia‐driven immunosuppression by Treg and type‐2 conventional dendritic cells in HCC	74
Impact of COVID‐19 Pandemic on Liver Transplantation and Alcohol‐Associated Liver Disease in the USA	74
Genetic Variation in HSD17B13 Reduces the Risk of Developing Cirrhosis and Hepatocellular Carcinoma in Alcohol Misusers	73
Inadequate Physical Activity and Sedentary Behavior Are Independent Predictors of Nonalcoholic Fatty Liver Disease	73
Impact of Immune Response on Outcomes in Hepatocellular Carcinoma: Association With Vascular Formation	73
Fecal Microbiome Distinguishes Alcohol Consumption From Alcoholic Hepatitis But Does Not Discriminate Disease Severity	72
Mitochondrial Double‐Stranded RNA in Exosome Promotes Interleukin‐17 Production Through Toll‐Like Receptor 3 in Alcohol‐associated Liver Injury	72
Tenofovir Versus Entecavir on Recurrence of Hepatitis B Virus–Related Hepatocellular Carcinoma After Surgical Resection	72
Long‐Term Study of Hepatitis Delta Virus Infection at Secondary Care Centers: The Impact of Viremia on Liver‐Related Outcomes	71
GALAD demonstrates high sensitivity for HCC surveillance in a cohort of patients with cirrhosis	71
Getting to HBV cure: The promising paths forward	71
Heterogeneity of HSCs in a Mouse Model of NASH	71
Endoplasmic reticulum stress in liver diseases	71
The associations between modifiable risk factors and nonalcoholic fatty liver disease: A comprehensive Mendelian randomization study	70
qFIBS: An Automated Technique for Quantitative Evaluation of Fibrosis, Inflammation, Ballooning, and Steatosis in Patients With Nonalcoholic Steatohepatitis	70
Indole Alleviates Diet‐Induced Hepatic Steatosis and Inflammation in a Manner Involving Myeloid Cell 6‐Phosphofructo‐2‐Kinase/Fructose‐2,6‐Biphosphatase 3	69
Extracellular vesicles derived from mesenchymal stem/stromal cells: The regenerative impact in liver diseases	67
NAFLD‐related hepatocellular carcinoma: The growing challenge	67
AASLD Practice Guidance: Palliative care and symptom‐based management in decompensated cirrhosis	67
The Use of Rifaximin in Patients With Cirrhosis	67
Effect of increased alcohol consumption during COVID‐19 pandemic on alcohol‐associated liver disease: A modeling study	65
Effect of diabetes medications and glycemic control on risk of hepatocellular cancer in patients with nonalcoholic fatty liver disease	64
Cure With Interferon‐Free Direct‐Acting Antiviral Is Associated With Increased Survival in Patients With Hepatitis C Virus‐Related Hepatocellular Carcinoma From Both East and West	64
Liver Transplantation Outcomes in a U.S. Multicenter Cohort of 789 Patients With Hepatocellular Carcinoma Presenting Beyond Milan Criteria	64
Insufficient Radiofrequency Ablation Promotes Hepatocellular Carcinoma Metastasis Through N6‐Methyladenosine mRNA Methylation‐Dependent Mechanism	64
Transcriptome Profiling Identifies TIGIT as a Marker of T‐Cell Exhaustion in Liver Cancer	63
Acute Hepatitis Is a Prominent Presentation of the Multisystem Inflammatory Syndrome in Children: A Single‐Center Report	63
Local and Regional Therapies for Hepatocellular Carcinoma	63
Reducing the Global Burden of Alcohol‐Associated Liver Disease: A Blueprint for Action	63
Metabolic dysfunction–associated fatty liver disease improves detection of high liver stiffness: The Rotterdam Study	62
Cordycepin Ameliorates Nonalcoholic Steatohepatitis by Activation of the AMP‐Activated Protein Kinase Signaling Pathway	62
Therapeutic Potential of TLR8 Agonist GS‐9688 (Selgantolimod) in Chronic Hepatitis B: Remodeling of Antiviral and Regulatory Mediators	62
The IKKβ‐USP30‐ACLY Axis Controls Lipogenesis and Tumorigenesis	62
Hydrogen Sulfide Alleviates Liver Injury Through the S‐Sulfhydrated‐Kelch‐Like ECH‐Associated Protein 1/Nuclear Erythroid 2–Related Factor 2/Low‐Density Lipoprotein Receptor–Related Protein 1 Pathway	61
Regional Differences in Human Biliary Tissues and Corresponding In Vitro–Derived Organoids	60
Reproductive Health and Liver Disease: Practice Guidance by the American Association for the Study of Liver Diseases	60
Genetics of Hepatocellular Carcinoma: Approaches to Explore Molecular Diversity	60
Liver Transplantation Following Yttrium‐90 Radioembolization: 15‐Year Experience in 207‐Patient Cohort	60
Transcriptional Dynamics of Hepatic Sinusoid‐Associated Cells After Liver Injury	60
Comparative Effectiveness of Entecavir Versus Tenofovir for Preventing Hepatocellular Carcinoma in Patients with Chronic Hepatitis B: A Systematic Review and Meta‐Analysis	60
Clinical Features of Patients Infected With Coronavirus Disease 2019 With Elevated Liver Biochemistries: A Multicenter, Retrospective Study	59
An Updated Assessment of Chronic Hepatitis B Prevalence Among Foreign‐Born Persons Living in the United States	59
Cirrhosis and Severe Acute Respiratory Syndrome Coronavirus 2 Infection in US Veterans: Risk of Infection, Hospitalization, Ventilation, and Mortality	59
Acute Kidney Injury in Decompensated Cirrhosis Is Associated With Both Hypo‐coagulable and Hyper‐coagulable Features	59
Glycemic Control Predicts Severity of Hepatocyte Ballooning and Hepatic Fibrosis in Nonalcoholic Fatty Liver Disease	59
The Commensal Microbe V eillonella as a Marker for Response to an FGF19 Analog in NASH	59
A revised electronic version of RUCAM for the diagnosis of DILI	59
Evolution of Systemic Therapy for Hepatocellular Carcinoma	58
Efficacy and Safety of Immunosuppression Withdrawal in Pediatric Liver Transplant Recipients: Moving Toward Personalized Management	58
Liver Injury in Liver Transplant Recipients With Coronavirus Disease 2019 (COVID‐19): U.S. Multicenter Experience	58
A Model Based on Noninvasive Markers Predicts Very Low Hepatocellular Carcinoma Risk After Viral Response in Hepatitis C Virus–Advanced Fibrosis	58
Lysyl Oxidase‐Like 4 Fosters an Immunosuppressive Microenvironment During Hepatocarcinogenesis	58
Serial Transient Elastography Examinations to Monitor Patients With Type 2 Diabetes: A Prospective Cohort Study	58
Loss‐of‐Function Genetic Screening Identifies Aldolase A as an Essential Driver for Liver Cancer Cell Growth Under Hypoxia	58
Liver‐Specific Deletion of Mouse Tm6sf2 Promotes Steatosis, Fibrosis, and Hepatocellular Cancer	57
Liver injury after SARS‐CoV‐2 vaccination: Features of immune‐mediated hepatitis, role of corticosteroid therapy and outcome	57
Immunotherapy as a Downstaging Therapy for Liver Transplantation	57
HLA‐B*35:01 and Green Tea–Induced Liver Injury	56
Rapid Turnover of Hepatitis B Virus Covalently Closed Circular DNA Indicated by Monitoring Emergence and Reversion of Signature‐Mutation in Treated Chronic Hepatitis B Patients	55
Genome‐wide Association Study and Meta‐analysis on Alcohol‐Associated Liver Cirrhosis Identifies Genetic Risk Factors	54

Response to Terlipressin and Albumin Is Associated With Improved Liver Transplant Outcomes in Patients With Hepatorenal Syndrome	54
Liver Disease and Coronavirus Disease 2019: From Pathogenesis to Clinical Care	53
Machine perfusion in liver transplantation	53
Liver zonation, revisited	53
The Emerging Role of B Cells in the Pathogenesis of NAFLD	53
Bidirectional Role of NLRP3 During Acute and Chronic Cholestatic Liver Injury	52
Genomic Analysis of Vascular Invasion in HCC Reveals Molecular Drivers and Predictive Biomarkers	52
Toll‐Like Receptor 8 Agonist GS‐9688 Induces Sustained Efficacy in the Woodchuck Model of Chronic Hepatitis B	52
Outcome of COVID‐19 in Patients With Autoimmune Hepatitis: An International Multicenter Study	51
Mortality and Hepatic Decompensation in Patients With Cirrhosis and Atrial Fibrillation Treated With Anticoagulation	51
PLAGL2‐EGFR‐HIF‐1/2α Signaling Loop Promotes HCC Progression and Erlotinib Insensitivity	50
Perspectives on the Neoadjuvant Use of Immunotherapy in Hepatocellular Carcinoma	50
Decreased Hepatocyte Autophagy Leads to Synergistic IL‐1β and TNF Mouse Liver Injury and Inflammation	50
Functional Comparison of Interferon‐α Subtypes Reveals Potent Hepatitis B Virus Suppression by a Concerted Action of Interferon‐α and Interferon‐γ Signaling	50
Monocytes as Potential Mediators of Pathogen‐Induced T‐Helper 17 Differentiation in Patients With Primary Sclerosing Cholangitis (PSC)	50
Group‐2 Innate Lymphoid Cells Promote HCC Progression Through CXCL2‐Neutrophil‐Induced Immunosuppression	50
Endothelial p300 Promotes Portal Hypertension and Hepatic Fibrosis Through C‐C Motif Chemokine Ligand 2–Mediated Angiocrine Signaling	50
Hepatic Fibrosis Associates With Multiple Cardiometabolic Disease Risk Factors: The Framingham Heart Study	50
Multiomics identifies the link between intratumor steatosis and the exhausted tumor immune microenvironment in hepatocellular carcinoma	50
Inflammation‐Induced Long Intergenic Noncoding RNA (LINC00665) Increases Malignancy Through Activating the Double‐Stranded RNA–Activated Protein Kinase/Nuclear Factor Kappa B Pathway in Hepatocellular	49
LSD1‐Demethylated LINC01134 Confers Oxaliplatin Resistance Through SP1‐Induced p62 Transcription in HCC	49
Hepatic Fat—Genetic Risk Score Predicts Hepatocellular Carcinoma in Patients With Cirrhotic HCV Treated With DAAs	49
Oral Vancomycin, Ursodeoxycholic Acid, or No Therapy for Pediatric Primary Sclerosing Cholangitis: A Matched Analysis	49
IL‐6–induced cGGNBP2 encodes a protein to promote cell growth and metastasis in intrahepatic cholangiocarcinoma	49
Cooperation Between MYC and β‐Catenin in Liver Tumorigenesis Requires Yap/Taz	49
AASLD practice guidance on drug, herbal, and dietary supplement–induced liver injury	49
Gut microbiota–derived short‐chain fatty acids regulate group 3 innate lymphoid cells in HCC	48
Intestinal Microbiome‐Macrophage Crosstalk Contributes to Cholestatic Liver Disease by Promoting Intestinal Permeability in Mice	48
Postvaccination COVID‐19 infection is associated with reduced mortality in patients with cirrhosis	48
Hemostatic Alterations in Patients With Cirrhosis: From Primary Hemostasis to Fibrinolysis	47
Liver Cancer Immunity	47
Black Patients Have Unequal Access to Listing for Liver Transplantation in the United States	47
Endoscopic Cyanoacrylate Injection Versus Balloon‐Occluded Retrograde Transvenous Obliteration for Prevention of Gastric Variceal Bleeding: A Randomized Controlled Trial	47
Shear stress–induced cellular senescence blunts liver regeneration through Notch–sirtuin 1–P21/P16 axis	47
Progressive cholestasis and associated sclerosing cholangitis are frequent complications of COVID‐19 in patients with chronic liver disease	47
Improving the Efficacy of Liver Cancer Immunotherapy: The Power of Combined Preclinical and Clinical Studies	47
Reply: A multi-society Delphi consensus statement on new fatty liver disease nomenclature	47
NAFLD and Alcohol‐Associated Liver Disease Will Be Responsible for Almost All New Diagnoses of Cirrhosis in Canada by 2040	46
Identifying an Optimal Liver Frailty Index Cutoff to Predict Waitlist Mortality in Liver Transplant Candidates	46
Molecular Characterization of Biliary Tract Cancer Predicts Chemotherapy and Programmed Death 1/Programmed Death‐Ligand 1 Blockade Responses	46
Eliminating METTL1‐mediated accumulation of PMN‐MDSCs prevents hepatocellular carcinoma recurrence after radiofrequency ablation	46
Phase 2 Study of Adjuvant Radiotherapy Following Narrow‐Margin Hepatectomy in Patients With HCC	46
Health disparities in chronic liver disease	45
Fatty Acid Synthase–Suppressor Screening Identifies Sorting Nexin 8 as a Therapeutic Target for NAFLD	45
MiR‐125b Loss Activated HIF1α/pAKT Loop, Leading to Transarterial Chemoembolization Resistance in Hepatocellular Carcinoma	45
Geographical similarity and differences in the burden and genetic predisposition of NAFLD	45
Immunosuppression Withdrawal in Liver Transplant Recipients on Sirolimus	45
Risk of Cirrhosis and Hepatocellular Cancer in Patients With NAFLD and Normal Liver Enzymes	45
Determination of Effective Albumin in Patients With Decompensated Cirrhosis: Clinical and Prognostic Implications	44
Relationship between NAFLD and coronary artery disease: A Mendelian randomization study	44
HBV RNA Profiles in Patients With Chronic Hepatitis B Under Different Disease Phases and Antiviral Therapy	44
Noninvasive Risk Stratification After HCV Eradication in Patients With Advanced Chronic Liver Disease	44
HBV/Pregenomic RNA Increases the Stemness and Promotes the Development of HBV‐Related HCC Through Reciprocal Regulation With Insulin‐Like Growth Factor 2 mRNA‐Binding Protein 3	44
Association of Metabolic Risk Factors With Risks of Cancer and All‐Cause Mortality in Patients With Chronic Hepatitis B	44
Activating Adenosine Monophosphate–Activated Protein Kinase Mediates Fibroblast Growth Factor 1 Protection From Nonalcoholic Fatty Liver Disease in Mice	44
Albumin in Advanced Liver Diseases: The Good and Bad of a Drug!	44
Microbiomics, Metabolomics, Predicted Metagenomics, and Hepatic Steatosis in a Population‐Based Study of 1,355 Adults	44
DNA Methylation Profiling of Human Hepatocarcinogenesis	44
Intratumoral γδ T‐Cell Infiltrates, Chemokine (C‐C Motif) Ligand 4/Chemokine (C‐C Motif) Ligand 5 Protein Expression and Survival in Patients With Hepatocellular Carcinoma	44
Multidisciplinary Management of Hepatic Hydrothorax in 2020: An Evidence‐Based Review and Guidance	44
Circulating Extracellular Vesicles Carrying Sphingolipid Cargo for the Diagnosis and Dynamic Risk Profiling of Alcoholic Hepatitis	43
Cirrhosis regression is associated with improved clinical outcomes in patients with nonalcoholic steatohepatitis	43
Paracentesis‐Induced Circulatory Dysfunction With Modest‐Volume Paracentesis Is Partly Ameliorated by Albumin Infusion in Acute‐on‐Chronic Liver Failure	43
Emerging Role of Genomic Analysis in Clinical Evaluation of Lean Individuals With NAFLD	43
Letter to the editor: Autoimmune hepatitis after COVID‐19 vaccination: A rare adverse effect?	43
Liver Stiffness by Transient Elastography to Detect Porto‐Sinusoidal Vascular Liver Disease With Portal Hypertension	43
Attributable Fractions of Nonalcoholic Fatty Liver Disease for Mortality in the United States: Results From the Third National Health and Nutrition Examination Survey With 27 Years of Follow‐up	43
Sirtuin 2 Prevents Liver Steatosis and Metabolic Disorders by Deacetylation of Hepatocyte Nuclear Factor 4α	43
Hepatocyte Nuclear Factor 4α Prevents the Steatosis‐to‐NASH Progression by Regulating p53 and Bile Acid Signaling (in mice)	42
Prospective Study of Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma on Waitlist for Liver Transplant	42
IL‐1 receptor antagonist plus pentoxifylline and zinc for severe alcohol‐associated hepatitis	42
A phase 2 dose‐finding study of lonafarnib and ritonavir with or without interferon alpha for chronic delta hepatitis	42
Ultrasensitive and affordable assay for early detection of primary liver cancer using plasma cell‐free DNA fragmentomics	42
Salidroside Activates the AMP‐Activated Protein Kinase Pathway to Suppress Nonalcoholic Steatohepatitis in Mice	41
BMS‐986263 in patients with advanced hepatic fibrosis: 36‐week results from a randomized, placebo‐controlled phase 2 trial	41
Functional Characterization of Organoids Derived From Irreversibly Damaged Liver of Patients With NASH	41
Current and Past Infections of HBV Do Not Increase Mortality in Patients With COVID‐19	41
An Endoplasmic Reticulum Stress–MicroRNA‐26a Feedback Circuit in NAFLD	41
Human Leukocyte Antigen B*14:01 and B*35:01 Are Associated With Trimethoprim‐Sulfamethoxazole Induced Liver Injury	41
Global burden of liver cancer in males and females: Changing etiological basis and the growing contribution of NASH	41
Angiotensin‐converting enzyme inhibitors prevent liver‐related events in nonalcoholic fatty liver disease	40
Diabetes medications and risk of HCC	40
Bile Acid Profiles in Primary Sclerosing Cholangitis and Their Ability to Predict Hepatic Decompensation	40
Microwave ablation versus laparoscopic resection as first‐line therapy for solitary 3–5‐cm HCC	40
Model for End‐Stage Liver Disease‐Lactate and Prediction of Inpatient Mortality in Patients With Chronic Liver Disease	40
The L‐α‐Lysophosphatidylinositol/G Protein–Coupled Receptor 55 System Induces the Development of Nonalcoholic Steatosis and Steatohepatitis	40
European Liver Transplant Registry: Donor and transplant surgery aspects of 16,641 liver transplantations in children	40
Genomic Characterization of Cholangiocarcinoma in Primary Sclerosing Cholangitis Reveals Therapeutic Opportunities	40
T‐Cell Immunoglobulin and Mucin Domain‐Containing Protein‐4 Is Critical for Kupffer Cell Homeostatic Function in the Activation and Resolution of Liver Ischemia Reperfusion Injury	40
L‐ornithine L‐aspartate in acute treatment of severe hepatic encephalopathy: A double‐blind randomized controlled trial	40
Farnesoid X Receptor Activation Impairs Liver Progenitor Cell–Mediated Liver Regeneration via the PTEN‐PI3K‐AKT‐mTOR Axis in Zebrafish	40
Placebo effect on progression and regression in NASH: Evidence from a meta‐analysis	39
Mechanistic Rationales Guiding Combination Hepatocellular Carcinoma Therapies Involving Immune Checkpoint Inhibitors	39
HCC incidence after hepatitis C cure among patients with advanced fibrosis or cirrhosis: A meta‐analysis	39
Tumor‐derived exosomes induce immunosuppressive macrophages to foster intrahepatic cholangiocarcinoma progression	39